OBJECTIVE: To examine (1) moderating effects of oppositional defiant disorder (ODD) on attention-deficit/hyperactivity disorder (ADHD) treatment response and (2) responses of ODD symptoms to atomoxetine. METHOD: Children and adolescents (ages 8-18) with ADHD were treated for approximately 8 weeks withplacebo or atomoxetine (fixed dosing: 0.5, 1.2, or 1.8 mg/kg/day, b.i.d.) under randomized, double-blind conditions. Among patients with lifetime diagnostic information (n = 293), 39% were diagnosed with comorbid ODD and 61% were not. Treatment-group differences and differences between patients with and without comorbid ODD were examined post hoc for changes on the Attention-Deficit/Hyperactivity Disorder Rating Scale IV-Parent version, investigator-administered and -scored; Conners' Parent Rating Scale-Revised Short Form; Clinical Global Impressions Severity of ADHD Scale; and the parent-rated Child Health Questionnaire. RESULTS:Youths with ADHD and comorbid ODD showed statistically significant improvement in ADHD, ODD, and quality-of-life measures. Treatment response was similar in youths with and without ODD, except that the comorbid group showed improvement compared with placebo at 1.8 mg/kg/day but not 1.2 mg/kg/day. In contrast, youths without ODD showed improvement at 1.2 mg/kg/day and no incremental benefit at 1.8 mg/kg/day. CONCLUSIONS:Atomoxetine treatment improves ADHD and ODD symptoms in youths with ADHD and ODD, although the comorbid group may require higher doses.
RCT Entities:
OBJECTIVE: To examine (1) moderating effects of oppositional defiant disorder (ODD) on attention-deficit/hyperactivity disorder (ADHD) treatment response and (2) responses of ODD symptoms to atomoxetine. METHOD:Children and adolescents (ages 8-18) with ADHD were treated for approximately 8 weeks with placebo or atomoxetine (fixed dosing: 0.5, 1.2, or 1.8 mg/kg/day, b.i.d.) under randomized, double-blind conditions. Among patients with lifetime diagnostic information (n = 293), 39% were diagnosed with comorbid ODD and 61% were not. Treatment-group differences and differences between patients with and without comorbid ODD were examined post hoc for changes on the Attention-Deficit/Hyperactivity Disorder Rating Scale IV-Parent version, investigator-administered and -scored; Conners' Parent Rating Scale-Revised Short Form; Clinical Global Impressions Severity of ADHD Scale; and the parent-rated Child Health Questionnaire. RESULTS: Youths with ADHD and comorbid ODD showed statistically significant improvement in ADHD, ODD, and quality-of-life measures. Treatment response was similar in youths with and without ODD, except that the comorbid group showed improvement compared with placebo at 1.8 mg/kg/day but not 1.2 mg/kg/day. In contrast, youths without ODD showed improvement at 1.2 mg/kg/day and no incremental benefit at 1.8 mg/kg/day. CONCLUSIONS:Atomoxetine treatment improves ADHD and ODD symptoms in youths with ADHD and ODD, although the comorbid group may require higher doses.
Authors: Ferenc Martenyi; Nikolay N Zavadenko; Natalia B Jarkova; Alexandr A Yarosh; Victoria O Soldatenkova; Leonid M Bardenstein; Irina A Kozlova; Nikolay G Neznanov; Olga I Maslova; Andrey S Petrukhin; Nina K Sukchotina; Valeriy P Zykov Journal: Eur Child Adolesc Psychiatry Date: 2009-07-01 Impact factor: 4.785
Authors: Victoria K Robson; Christian Stopp; David Wypij; Carolyn Dunbar-Masterson; David C Bellinger; David R DeMaso; Leonard A Rappaport; Jane W Newburger Journal: J Pediatr Date: 2018-09-28 Impact factor: 4.406
Authors: Oscar G Bukstein; L Eugene Arnold; Jeanne M Landgraf; Paul Hodgkins Journal: Child Adolesc Psychiatry Ment Health Date: 2009-12-10 Impact factor: 3.033
Authors: Ralf W Dittmann; Peter M Wehmeier; Alexander Schacht; Anette Minarzyk; Martin Lehmann; Kathrin Sevecke; Gerd Lehmkuhl Journal: Child Adolesc Psychiatry Ment Health Date: 2009-08-24 Impact factor: 3.033